[Federal Register Volume 80, Number 147 (Friday, July 31, 2015)]
[Notices]
[Pages 45663-45664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18756]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY:  Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Julie Mass[egrave], Pennsylvania State University (PSU): Based on 
an assessment conducted by the Pennsylvania State University College of 
Medicine (PSU-COM) and the Respondent's admission, ORI and PSU found 
that Ms. Julie Mass[egrave], former postdoctoral scholar, PSU-COM, 
engaged in research misconduct in research supported by National Cancer 
Institute (NCI), National Institutes of Health (NIH), grant 4 R00 
CA138498.
    ORI found that the Respondent knowingly engaged in research 
misconduct by falsifying and/or fabricating Western blot data and 
analyses that were including in the following manuscript:
     ``Cellular invasion following p120-catenin loss is 
mediated by AP-1, ITGA2 and MMP11,'' submitted to Molecular Cancer 
Research (hereafter referred to as the ``Molecular Cancer Research 
manuscript'').
    ORI found that the Respondent knowingly falsified and/or fabricated 
Western blot images, by manipulating the images to give the desired 
results, and quantitative PCR data and cell invasion and migration 
data, which were included in Figures 2, 3, S1, and S2 in the Molecular 
Cancer Research manuscript.
    Specifically, ORI found that the Respondent included falsified and/
or fabricated data and images in the following figures, and the 
corresponding text, in the Molecular Cancer Research manuscript:
    1. Bands were cut and pasted from different Western blots for the 
following figures:
    a. Figures 2A, lanes 2 and 3, for P-cJun (S73)
    b. Figure 2D, lanes 4 and 6, bands identified as ITGA2
    c. Figure 3B, bands identified as ITGA2 and MMP11
    d. Figure 3D, bands identified as ITGA2 and MMP11 for lanes M2Neo-
[uarr]ITGA2 control and [darr]MMP1
    e. Figure 3E, bands identified as ITGA2 and MMP11 for lanes M2KO-
[darr]ITGA2 control and M2KO-[darr]ITGA2-[uarr]MMP11
    f. Figure S1A, bands identified as P-cJun (S73)
    g. Figure S2A, bands identified as P-cJun (S73)
    h. Figure S2C, bands identified as P-cJun (S73)
    i. Figure S2E, bands identified ITGA2 and MMP11
    j. Figures S4B and C, identical bands were used for [beta]-actin
    2. Numbers were increased or decreased in cell invasion and 
migration assays to give the desired results in the following figures:
    a. Figure 2B, for M2KO-DMSO cells and M2KO-SR11302 cells
    b. Figure 3F, for M2Neo-[uarr]ITGA2 [darr]MMP11
    c. Figure 3G, for M2KO-[darr]ITGA2 [uarr]MMP11
    d. Figure S1B, for F2KO-cJun peptide
    e. Figure S2B, for F2KO-cJun DMSO and F2KO-cJun SR11302
    f. Figure S2D, for F2KO-cJun peptide
    g. Figure S2F, for F2Tom-[uarr]ITGA2 and F2KO-[darr]ITGA2 peptide
    h. Figures S4A, B, C, and D, for the migration for M2KO and F2KO 
cells
    3. qPCR numbers were altered in Figure 2C, for M2KO-DMSO-PcJun ChIP 
and for M2KO-SR11302-PcJun ChIP, to give the desired result of PcJun 
binding to ITGA2 promoter.
    Ms. Mass[egrave] has entered into a Voluntary Settlement Agreement 
and has voluntarily agreed for a period of two (2) years, beginning on 
July 6, 2015:
    (1) To have her research supervised; Respondent agreed that prior 
to the submission of an application for U.S. Public Health Service 
(PHS) support for a research project on which her participation is 
proposed and prior to her participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision 
of her duties is submitted to ORI for approval; the supervision plan 
must be designed to ensure the scientific integrity of her research 
contribution; Respondent agreed that she will not participate in any 
PHS-supported research until such a supervision plan is submitted to 
and approved by ORI; Respondent agreed to maintain responsibility for 
compliance with the agreed upon supervision plan;
    (2) that any institution employing her shall submit in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual

[[Page 45664]]

experiments or are otherwise legitimately derived, and that the data, 
procedures, and methodology are accurately reported in the application, 
report, manuscript, or abstract; and
    (3) to exclude herself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-18756 Filed 7-30-15; 8:45 am]
 BILLING CODE 4150-31-P